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Abstract
Background: The blood HIV RNA viral load is the best-defined predictor of HIV transmission, in part due to ease of
measurement and the correlation of blood and genital tract (semen or cervico-vaginal) viral load, although recent studies
found semen HIV RNA concentration to be a stronger predictor of HIV transmission. There is currently no standardized
method for semen collection when measuring HIV RNA concentration. Therefore, we compared two collection techniques in
order to study of the impact of antiretroviral therapy on the semen viral load.
Methodology/Principal Findings: Semen was collected by masturbation from HIV-infected, therapy-naı ¨ve men who have
sex with men (MSM) either undiluted (Visit 1) or directly into transport medium (Visit 2). Seminal plasma was then isolated,
and the HIV RNA concentration obtained with each collection technique was measured and corrected for dilution if
necessary. Collection of semen directly into transport medium resulted in a median HIV RNA viral load that was 0.4 log10
higher than undiluted samples.
Conclusions/Significance: The method of semen collection is an important consideration when quantifying the HIV RNA
viral load in this compartment.
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Introduction
Globally there were an estimated 2.6 million new HIV-1 (HIV)
infections in 2009 [1], most acquired through sex. The blood HIV
RNA viral load is the best defined predictor of HIV transmission
[2], probably because it is easily measured and tends to correlate
with the genital tract (semen or cervico-vaginal) viral load [3].
However, recent studies have found that the semen HIV RNA
viral load is a stronger independent predictor of HIV transmission
than the blood viral load [4].
Following the initiation of antiretroviral therapy (ART) blood
HIV RNA concentrations generally decrease to undetectable levels,
in association with a 92% reduction in HIV transmission risk in a
recent observational study [5]. However, a significant minority of
individuals continue to have detectable levels of viral RNA in semen
despite an undetectable HIV RNA blood VL, sometimes at very
high levels [6]. Whether this phenomenon underpins the inability of
ART to completely prevent HIV transmission is not clear. Research
studies to clarify these issues will require well-validated assays to
measure semen HIV RNA viral load, something which is more
technically challenging than measurement of the blood VL due to
the presence in semen of PCR inhibitors, endonucleases and other
factors [7]. While commercially available molecular assays may be
more reliable and reproducible than in-house assays [8], in this
study we evaluatedtheimpact ofdifferent semen collection methods
on the HIV RNA level in ART-naı ¨ve men.
Methods
Human Subjects
HIV-infected, antiretroviral therapy-naı ¨ve men who have sex
with men (MSM) were recruited through the Canadian Immuno-
deficiency Research Collaborative at the Maple Leaf Medical
Clinic in Toronto, Canada. Participants were excluded if at either
visit they had clinical urethritis, genital ulcer disease, laboratory
evidence of infection by C. trachomatis,o rN. gonorrhoeae by urine
nucleic acid amplification testing (NAAT: Amplicor CT/NG
assay, Roche Diagnostic Systems), or active T. pallidum infection by
serology (RPR; rapid plasma reagin). A first-void urine dipstick for
leukocytes was also performed to screen for asymptomatic
urethritis. All participants provided informed, written consent;
ethical approval for this study was obtained through the research
ethics board of the University of Toronto.
Sample acquisition, processing and viral load
measurement
Paired blood and semen specimens were collected within an
hour of each other at two separate study visits. Semen samples
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23654were collected by masturbation into a dry sterile container
(undiluted) at visit 1, and directly into 10 mL of sterile RPMI
1640 (Gibco) containing 100 U/mL penicillin and 100 mg/mL
streptomycin (Gibco) (transport medium) at visit 2. All study
participants agreed to abstain from sexual intercourse or
masturbation for 48 hours prior to sample donation. All samples
were processed within 2 hours of collection. Seminal plasma was
cryopreserved at 280uC after sample centrifugation at 850 g for
10 minutes. Blood plasma was collected and cryopreserved after
ficoll density gradient centrifugation at 500 g for 25 minutes.
Blood and semen plasma HIV-1 RNA concentrations were
measured in the Mount Sinai Hospital Department of Microbi-
ology (accredited by the Ontario Public Health Lab for clinical
HIV-1 viral load measurement) using the Versant HIV-1 RNA 3.0
assay (bDNA; Bayer Diagnostics; lower limit of detection, 50 RNA
copies/mL). Correction for semen dilution at visit 2 was calculated
based on the total sample volume provided; since transport
medium was occasionally spilled during semen collection, where
the returned total volume (semen and transport medium) was
lower than the original volume of transport medium, we assumed
a semen volume of 2 ml (the mean volume of undiluted samples
collected during visit 1).
Statistical analysis
All analyses were formed with SPSS software (version 18; SPSS).
Data were statistically analyzed using the non-parametric paired
Wilcoxon signed rank test for median measurements and changes
in mean VL measurements. Statistical significance was defined as
p,0.05.
Results
Twenty-seven participants were recruited; the median CD4
+ T
cellcount was 550/mm
3 (range, 320–1210 mm
3) at visit 1 and 470/
mm
3 (range, 160–780 mm
3) at visit 2. There was no statistically
significant difference in the CD4 counts between visits (Wilcoxon
paired p=0.383), although one individual at visit 2 had progressed
to AIDS based on a CD4 count ,200 mm
3 (160 mm
3). No
participant had a prior history of an AIDS-defining illness (at either
study visit), and no participant had syphilis, N. gonorrhea or C.
trachomatis infection by NAAT, clinical urethritis, genital ulcer
disease or leukocytes detected on dipstick of first void urine. Study
visits were a median of 6 months apart, and there was no difference
in the blood HIV RNA VL (4.26 vs. 4.35 log10 RNA copies/mL,
Visit 1 vs. Visit 2; p=0.274) between visits. Five participants
(18.5%) had an undetectable semen VL by at least one of the two
collection methods (i.e.: at e1 study visit), and in 4/5 the semen VL
was undetectable at both study visits: for practical reasons these 4
participants were not included in the comparison of sampling
techniques.
In those participants with a detectable semen VL during at least
one study visit, the median HIV load as measured in undiluted
semen (Visit 1) was 0.42 log10 copies/mL (2,236 copies/mL) lower
than that measured in semen that had been collected directly into
transport medium. Median semen HIV RNA collected undiluted
was 3.14 log10 copies/mL (1,396 RNA copies/mL, range, 50-
210,350 RNA copies/mL) vs. 3.56 log10 copies/mL (3,631 RNA
copies/mL, range, ,300–1,002,030 RNA copies/mL) when
collected into transport media (Figure 1; p=0.012).
The proportion of participants with any detectable HIV RNA
in semen did not vary by collection technique (21/27 undiluted vs.
20/27 diluted; p=NS). As expected, having an undetectable
semen VL at one visit increased the probability of remaining
undetectable at the next (LR=6.0; p=0.014). An estimated semen
volume of 2 mL was used at visit 2 for 14/27 participants who had
spilled transport medium during sample collection (see Methods
section, above). When these participants were excluded, our
overall results were unchanged with a median semen HIV
concentration of 2.88 log10 at visit 1 and 3.56 at visit 2 (median
difference 0.68 log10, p=0.033).
Discussion
This study demonstrates that the method of semen collection
can have a substantial impact on semen HIV RNA VL
measurements, and this should be an important consideration
when performing and assessing studies of semen HIV RNA load.
The cause of the reduced level when measuring the HIV RNA VL
in semen that had been collected undiluted is not clear, but might
relate to PCR inhibitors present in undiluted semen [9] or to the
presence in semen of various enzymes and other immune factors
[10–11]; certainly, seminal plasma is well described to have
substantial cytotoxic effects [12]. Interestingly, while the semen
viral load was significantly higher when collected into transport
medium, there was no difference between collection methods in
the proportion of participants who had any detectable semen HIV
RNA. We hypothesize that this may be because although
collection into RPMI medium was associated with an increased
semen HIV RNA level, this also diluted the sample approximately
six-fold, decreasing our assay limit of detection from d50 to d300
HIV RNA copies/mL.
The second study visit, when semen VL was assayed in a diluted
sample, was 6 months after the semen VL was measured
undiluted. This raises the possibility that a higher semen VL
might represent HIV disease progression. However, the fact that
both the blood VL and CD4+ T cell count were unchanged
between visits strongly suggests that this was not the case. The
semen HIV concentration may be more variable than that in
blood plasma, and in addition there is considerable variability of
all HIV RNA assays currently in clinical use. However, neither of
these sources of variability would explain our observation that the
semen HIV viral load was significantly and consistently higher
when samples were collected into transport medium rather than
Figure 1. Blood and semen HIV RNA viral load. Blood was
collected and the HIV RNA viral load assayed the same way at both
study visits (BVL1 and BVL2, respectively); semen was collected
undiluted at visit 1 (SVL1) and directly into transport medium and visit
2 (SVL2). Participants with an undetectable semen viral load at both
study visits were excluded from statistical analysis.
doi:10.1371/journal.pone.0023654.g001
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blunted our ability to find such a difference. In addition, in those
participants with a spilled sample at visit two, if we assumed a
volume equal to their first sample, the difference in semen viral
loads across the two collection methods was still statistically
significant.
Overall, our findings suggest that semen collection technique is
an important consideration if the semen viral load is to be assessed
quantitatively, since immediate collection of semen into transport
medium was associated with higher semen HIV RNA concentra-
tion that that measured into semen collected undiluted. However,
this would less critical if the goal were to deem semen HIV RNA
as being ‘‘detectable’’ or ‘‘undetectable’’, since these proportions
were not altered by collection technique.
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